Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07505199RecruitingPhase 1
Immune cell therapy for advanced heart failure from blocked arteries
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07505472RecruitingPhase 2/Phase 3
Short radiation plus chemo and immunotherapy for high-risk rectal cancer
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Changchun, JilinAges 18–75 - NCT05583006Recruiting
Switch from entecavir to tenofovir for chronic hepatitis B
This trial studies switching people with chronic hepatitis B from entecavir (ETV) to tenofovir alafenamide (TAF). It may help if you feel your current entecavir treatment isn’t working well enough or is inconvenient.
Taichung, TaiwanAges 20 years+ - NCT06767436Recruiting
Real-world study of Enhertu for advanced gastric cancer
This study looks at how well the drug Trastuzumab Deruxtecan works and how safe it is in real-world patients with advanced stomach or gastroesophageal cancer whose tumors are HER2-positive. The goal is to gather more information beyond what was learned in clinical trials.
Seoul, SeoulAges 19 years+ - NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT07491016Recruiting
Telitacicept plus baricitinib for hard-to-treat rheumatoid arthritis
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
Hangzhou, ZhejiangAges 18–85 - NCT07498517RecruitingPhase 2
Single dose of gruticibart to prevent blood clot complications
This trial tests if a single dose of a drug called gruticibart can help prevent blood clots caused by a central line (a special IV tube) inserted for cancer treatment. It may be an option for adults starting therapy that requires this type of IV access.
Portland, OregonAges 18 years+ - NCT07495397Recruiting
Daphnetin plus chemo for advanced ovarian cancer maintenance
This trial is testing a combination of two drugs—daphnetin capsules and a standard chemotherapy (TC regimen)—as a targeted maintenance therapy after initial surgery for advanced ovarian cancer. The goal is to see if this treatment can help keep the cancer from coming back.
Changchun, JilinAges 18–75 - NCT07493824RecruitingPhase 4
Study of Paiteling Antibacterial Liquid for Persistent HPV Infection
This trial tests an antibacterial liquid (Paiteling®) to see if it can clear a persistent high-risk HPV infection of the cervix. It may be an option for women whose HPV has lasted 2 years or more and whose cervical biopsy shows only mild changes.
Changchun, JilinAges 26–65 - NCT07492693RecruitingPhase 2
Preventing low platelets from chemo in GI cancers
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
ShanghaiAges 18 years+ - NCT07495384Recruiting
CapsuleX and cisplatin for platinum-resistant ovarian cancer
This study tests a new treatment combination (CapsuleX plus cisplatin) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help when the cancer has progressed within 6 months of last platinum treatment.
Changchun, JilinAges 18 years+ - NCT07491146RecruitingPhase 2
Study of HSK55718 for pain after abdominal surgery
This trial tests a new medicine, HSK55718, to see if it safely reduces pain after planned abdominal surgery. It is for adults who have moderate or severe pain after surgery and are otherwise in good health.
Changsha, HunanAges 18 years+ - NCT07490041RecruitingEarly Phase 1
CAR-NK cell therapy for refractory childhood rheumatic diseases
This trial is testing a new type of cell therapy (CAR-NK cells) that targets two markers on immune cells (CD19 and BCMA) to treat severe forms of childhood rheumatic diseases. It aims to see if this treatment is safe and can help when other medicines have failed.
Hangzhou, ZhejiangAges 5 years+ - NCT07498374Recruiting
Drug-eluting stent for eosinophilic sinusitis with nasal polyps
This trial tests a fully dissolvable stent that releases medication inside the sinuses after surgery. It is for patients with a specific type of sinusitis (eosinophilic) and nasal polyps who either need surgery or have had surgery and show early signs of inflammation returning.
Xi'an, ShaanxiAges 18–65 - NCT07496021Recruiting
Probiotic for early Alzheimer's: safety and memory benefits
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Gyeonggi-doAges 55–85 - NCT07493265RecruitingPhase 2
Study of E2086 for adults with narcolepsy
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
Santa Ana, CaliforniaAges 18 years+ - NCT07495852RecruitingPhase 3
Implant for eye pressure in glaucoma or ocular hypertension
This trial tests a tiny implant that slowly releases medication inside the eye to lower pressure. It is for people with open-angle glaucoma or high eye pressure who have not had certain eye surgeries.
Dothan, AlabamaAges 18 years+ - NCT07489651RecruitingPhase 2
New treatment for generalized anxiety disorder
This trial tests a new medication called RE104 for people with generalized anxiety disorder (GAD). The goal is to see if it helps reduce anxiety symptoms safely.
Birmingham, AlabamaAges 18–74 - NCT07494409RecruitingPhase 3
A new oral medicine for anemia in dialysis patients
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
ShanghaiAges 18–75 - NCT07498478RecruitingPhase 2
Tinengotinib and fulvestrant for advanced HR+ HER2- breast cancer
This trial tests a new drug called tinengotinib combined with the hormone therapy fulvestrant for people with HR-positive, HER2-negative breast cancer that has come back or spread. It is for those who have already tried a CDK4/6 inhibitor and at least one hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07494305RecruitingPhase 2
Testing a new drug for bipolar depression
This trial tests an investigational drug called LB-102 for people with bipolar I disorder who are currently experiencing a major depressive episode without psychosis. It aims to see if the drug is safe and effective for treating depression symptoms.
Bentonville, ArkansasAges 18–65 - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT06632613RecruitingPhase 2
Trial of ENN0403 to prevent kidney injury after heart surgery
This study tests a new drug (ENN0403) given during heart surgery to see if it prevents acute kidney injury—a sudden drop in kidney function. The trial is for people who are already at higher risk due to their specific heart surgery and other health factors.
ShanghaiAges 18–85 - NCT06744907RecruitingPhase 4
Betadine under skin during back fusion surgery
This study tests whether a small amount of Betadine placed under the skin during back fusion surgery can help prevent infection. It's for people having their first posterior spinal fusion.
Akron, OhioAges Up to 26 years
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.